Rochelle, Virginia (May 23, 2018) – NDA Partners Chairman Carl Peck, MD, announced today that Bruce Green, D.Ph, an internationally recognized expert in the field of pharmacometrics, rare diseases, pediatric drug development, and dosing in obesity, has joined the firm as an Expert Consultant.
Dr. Green was a former US Food and Drug Administration (FDA) Guest Reviewer in the Office of Clinical Pharmacology and Biopharmaceutics and a Tenured Senior Lecturer in the School of Pharmacy at the University of Queensland, Australia. He has held a Research Scientist position in the Center for Drug Development Science, University of California and was a Research Pharmacist at the Royal Brisbane Hospital, Australia.
Dr. Green has a keen interest in using modeling and simulation from pre-clinical through to post-marketing commitments. He maintains a research presence via his visiting Senior Lecturer position at the School of Pharmacy, King’s College London, London University and as an Adjunct Associate Professor in the School of Pharmacy at the University of Queensland, Australia.
“Dr. Green’s expertise in the field of pharmacometrics, rare diseases, pediatric drug development, and use of modeling and simulation from pre-clinical through to post-marketing commitments will provide great benefit to our clients in the early drug development process,” said Dr. Peck. “We are pleased that he has joined NDA Partners.”
Dr. Green earned his doctorate degree from the University of Queensland in Australia, a master’s degree from Brighton University in England, and a bachelor’s degree in Pharmacy from King’s College London in England.
About NDA Partners
NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Earle Martin, Chief Executive Officer